PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Interfractional Rectal Displacement Requiring Repeated Precaution Did Not Correlate to Biochemical Control and Rectal Toxicity in Patients with Prostate Cancer Treated with Image-guided Intensity-modulated Radiation Therapy.

Abstract To investigate the correlation between frequency of action level of interfractional rectal displacement requiring repeated precaution in patients with prostate cancer and late toxicity from image-guided intensity-modulated radiation therapy (IG-IMRT) using helical tomotherapy.
PMID
Related Publications

Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.

Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance.

Dosimetric and radiobiological consequences of computed tomography-guided adaptive strategies for intensity modulated radiation therapy of the prostate.

Long-term Tumor Control and Late Toxicity in Patients with Prostate Cancer Receiving Hypofractionated (2.2 Gy) Soft-tissue-matched Image-guided Intensity-modulated Radiotherapy.

Frequency and predisposing factors for interfractional rectal displacement requiring repeated precaution in prostate cancer patients treated with image-guided intensity-modulated radiation therapy.

Authors

Mayor MeshTerms
Keywords

IG-IMRT

Tomotherapy

biochemical control

late toxicity

prostate cancer

Journal Title anticancer research
Publication Year Start




PMID- 28982897
OWN - NLM
STAT- MEDLINE
DCOM- 20171016
LR  - 20171016
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 10
DP  - 2017 Oct
TI  - Interfractional Rectal Displacement Requiring Repeated Precaution Did Not
      Correlate to Biochemical Control and Rectal Toxicity in Patients with Prostate
      Cancer Treated with Image-guided Intensity-modulated Radiation Therapy.
PG  - 5755-5760
AB  - AIM: To investigate the correlation between frequency of action level of
      interfractional rectal displacement requiring repeated precaution in patients
      with prostate cancer and late toxicity from image-guided intensity-modulated
      radiation therapy (IG-IMRT) using helical tomotherapy. PATIENTS AND METHODS: We
      examined 264 patients who underwent IG-IMRT during 2007-2011. Megavoltage
      computed tomographic (MVCT) images were acquired before radiation therapy and was
      examined with soft-tissue matching by comparing treatment planning images within 
      9,345 fractions. Displacement of the anterior rectal region larger than 5 mm,
      requiring repeated precaution, was defined as the level of rectal displacement
      requiring action (ARD). RESULTS: ARD was identified in 815 (7.7%) out of 9,345
      fractions and at least once in 82% (216/264) of patients. The highest incidence
      of ARD (11%) was found during the initial week of treatment (first five and next 
      five fractions), after which the incidence decreased to 6% (p<0.0001). Patients
      with lean body (lower body mass index (BMI) tended to have a higher incidence of 
      ARD. We identified 16 (6%) cases of gastrointestinal toxicity and 12 (4.5%)
      genitourinary toxicities as a late adverse reaction (3 months or later after
      IG-IMRT). There was no correlation between ARD and late toxicity.
      Prostate-specific antigen (PSA) control was also similar (p=0.12) between those
      with ARD (96% at 5 year) and those without ARD (88%). CONCLUSION: ARD occurred
      predominantly in lean patients, during the initial week of treatment and became
      less likely over time. ARD was not correlated to late toxicity and PSA control,
      therefore, IG-IMRT technique was able to adequately control error due to
      interfractional prostate and rectal motion.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Iwama, Kazuki
AU  - Iwama K
AD  - Department of Radiology, Ujitakeda Hospital, Uji, Japan.
FAU - Yamazaki, Hideya
AU  - Yamazaki H
AD  - Department of Radiology, Ujitakeda Hospital, Uji, Japan [email protected]
AD  - Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural
      University of Medicine, Kamigyo, Japan.
FAU - Shimizu, Daisuke
AU  - Shimizu D
AD  - Department of Radiology, Ujitakeda Hospital, Uji, Japan.
AD  - Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural
      University of Medicine, Kamigyo, Japan.
FAU - Suzuki, Gen
AU  - Suzuki G
AD  - Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural
      University of Medicine, Kamigyo, Japan.
FAU - Nakamura, Satoaki
AU  - Nakamura S
AD  - Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural
      University of Medicine, Kamigyo, Japan.
FAU - Sasaki, Naomi
AU  - Sasaki N
AD  - Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural
      University of Medicine, Kamigyo, Japan.
FAU - Takeneka, Tadashi
AU  - Takeneka T
AD  - Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural
      University of Medicine, Kamigyo, Japan.
FAU - Okabe, Haruumi
AU  - Okabe H
AD  - Department of Radiology, Ujitakeda Hospital, Uji, Japan.
FAU - Nishikawa, Tatsuyuki
AU  - Nishikawa T
AD  - Department of Radiology, Ujitakeda Hospital, Uji, Japan.
FAU - Yoshida, Ken
AU  - Yoshida K
AD  - Department of Radiology, Osaka Medical College, Takatsuki, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - EC 3.4.21.- (Kallikreins)
RN  - EC 3.4.21.- (kallikrein-related peptidase 3, human)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Dose Fractionation
MH  - Humans
MH  - Kallikreins/blood
MH  - Male
MH  - Middle Aged
MH  - Organs at Risk/diagnostic imaging/*radiation effects
MH  - Predictive Value of Tests
MH  - Prostate-Specific Antigen/blood
MH  - Prostatic Neoplasms/blood/diagnostic imaging/pathology/*radiotherapy
MH  - Radiation Injuries/drug therapy/etiology/*prevention & control
MH  - Radiotherapy Planning, Computer-Assisted/*methods
MH  - Radiotherapy, Image-Guided/adverse effects/*methods
MH  - Radiotherapy, Intensity-Modulated/adverse effects/*methods
MH  - Rectum/diagnostic imaging/*radiation effects
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Tomography, Spiral Computed
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *IG-IMRT
OT  - *Tomotherapy
OT  - *biochemical control
OT  - *late toxicity
OT  - *prostate cancer
EDAT- 2017/10/07 06:00
MHDA- 2017/10/17 06:00
CRDT- 2017/10/07 06:00
PHST- 2017/08/14 00:00 [received]
PHST- 2017/09/08 00:00 [revised]
PHST- 2017/09/14 00:00 [accepted]
PHST- 2017/10/07 06:00 [entrez]
PHST- 2017/10/07 06:00 [pubmed]
PHST- 2017/10/17 06:00 [medline]
AID - 37/10/5755 [pii]
AID - 10.21873/anticanres.12015 [doi]
PST - ppublish
SO  - Anticancer Res. 2017 Oct;37(10):5755-5760. doi: 10.21873/anticanres.12015.